|1.||Montefiori, David C: 4 articles (02/2012 - 03/2011)|
|2.||Ander, Bradley P: 3 articles (08/2015 - 01/2011)|
|3.||Jickling, Glen C: 3 articles (08/2015 - 01/2011)|
|4.||Zhang, Xiaoyan: 3 articles (01/2015 - 12/2012)|
|5.||Abbruzzese, Alberto: 3 articles (04/2013 - 12/2004)|
|6.||Marra, Monica: 3 articles (04/2013 - 12/2004)|
|7.||Caraglia, Michele: 3 articles (04/2013 - 12/2004)|
|8.||Pipe, Steven W: 3 articles (05/2012 - 05/2008)|
|9.||Robinson, Harriet L: 3 articles (02/2012 - 03/2011)|
|10.||Kozlowski, Pamela A: 3 articles (02/2012 - 03/2011)|
07/01/1986 - "At comparable antiviral concentrations, natural lymphoblastoid IFN, IFN-alpha Con1, the molecular subtype IFN-alpha, and the hybrid IFN-alpha AD(Bgl) obtained by recombinant DNA methods conferred similar protection against herpes simplex virus type 1 and type 2 (HSV-2) infections of human cells in vitro. "
11/15/1991 - "Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection."
04/01/1985 - "Recombinant DNA techniques in the study of hepatitis B virus infection."
11/01/2013 - "The porcine BMP-2 gene lentiviral vector was constructed by recombinant DNA technology and was used to transfect BMSCs at multiplicity of infection (MOI) of 10, 25, 50, 100, and 200, then the optimal value of MOI was determined by fluorescent microscope and inverted phase contrast microscope. "
08/12/2008 - "These results indicate that the use of a recombinant DNA vaccine can provide protective immunity against mycobacterial infection by inducing a Th1 response."
12/01/2009 - "Advances in recombinant DNA technology have allowed the development of viruses that are tumor-selective and armed with transgenes, increasing the application potential and efficacy of this novel anticancer therapy. "
01/01/2010 - "This study demonstrates how alternatively spliced genes can reliably be identified in a cancer data set. "
01/01/2007 - "In this study, a recombinant DNA vaccine candidate, termed HPV16-DNA-E6E7, constructed with HPV16 E7 and E6 genes was generated and used to against HPV16-induced tumors. "
02/01/2001 - "However, the results of this study suggest that differential growth conditions within tumors could markedly affect the expression of recombinant DNA under control of both inducible and constitutive promoters. "
01/01/1993 - "Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials."
03/01/1990 - "Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months."
09/01/2004 - "[Application of exponent curve model to study the hepatitis B DNA recombinant yeast derived vaccine antibody levels]."
03/01/1999 - "Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children."
10/01/1993 - "Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses."
11/01/1991 - "The purpose of this study was to determine if a hepatitis B vaccination schedule initiated with one recombinant DNA vaccine could be completed with another. "
|4.||Hemophilia A (Haemophilia)
04/01/1997 - "A prospective, open-label multicenter investigation has been conducted to compare pharmacokinetic parameters of recombinant DNA-derived FVIII (rFVIII) and plasma-derived FVIII concentrate (pdFVIII) and to assess safety and efficacy of long-term home-treatment with rFVIII for subjects with hemophilia A. "
03/01/1988 - "Together with a previously published assay for FVIII-LC it has now become possible to measure the relative amounts of FVIII-HC and FVIII-LC in haemophilia A plasma and to study the separate expression of FVIII-HC and FVIII-LC by recombinant DNA technology. "
05/01/1995 - "Use of recombinant DNA-derived fVIII as well as gene therapy could make hemophilia treatment independent of blood-derived products. "
10/01/1990 - "Recombinant DNA methods in hemophilia A: carrier detection and prenatal diagnosis."
01/01/1987 - "[Diagnosis of hemophilia A and B by recombinant DNA methods]."
|5.||Communicable Diseases (Infectious Diseases)
11/01/2008 - "Nonetheless, considerable advances have already been made, such as the eradication of certain infectious diseases and effective control of many others, and new technology is being developed in areas related to molecular biology, recombinant DNA, protein biochemistry, microbiology, and immunology. "
06/01/1993 - "The advent of recombinant DNA technology has already made a significant impact on various aspects related to the basic understanding of pathogenic mechanisms in infectious diseases, as well as practical applications related to diagnostics and prevention. "
01/01/1993 - "The possibility of preventing infectious diseases by employing efficacious vaccine is rapidly growing as a consequence of the new technologies in recombinant DNA and protein chemistry. "
06/05/1987 - "Recombinant DNA procedures have now been applied to the problem of the identification of molecular defects in man that account for heritable diseases, somatic mutations associated with neoplasia, and acquired infectious disease. "
05/01/1978 - "Recombinant DNA: an infectious disease perspective."
|3.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|4.||Proteins (Proteins, Gene)
|5.||Hepatitis B Surface Antigens (HBsAg)
|6.||hepatitis B hyperimmune globulin
|7.||Interferon-alpha (Interferon Alfa)
|2.||Drug Therapy (Chemotherapy)